Lynch Thomas G 4
4 · Evofem Biosciences, Inc. · Filed Jul 1, 2019
Insider Transaction Report
Form 4
Lynch Thomas G
Director
Transactions
- Exercise/Conversion
Restricted Stock Units
2019-06-30−37,500→ 112,500 total→ Common Stock (37,500 underlying) - Exercise/Conversion
Common Stock
2019-06-30+37,500→ 212,500 total
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019.
- [F2]The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020.